G.P. Sarmiento et al. / European Journal of Medicinal Chemistry 46 (2011) 101e105
105
extracted with several portions of dichloromethane. The organic
extract was dried with anhydrous Na2SO4 and the solvent was
removed in vacuo and was purified by p-TLC.
species for PIP showed MIC > 512 ug/ml. Interesting was to observe
the higher activity of compound 6 compared with those described
above. For this drug the range was from 2 to 32 ug/ml, except for C.
glabrata, for which MIC of >512 ug/ml was detected. All data is
summarized in Table 1.
5.1.3.1. 10-(3-Chloropropyl-)-10H-phenothiazine 5. It was obtained
as
chlorometane (1:1 v/v). Mp: 60e61 ꢁC, yield 88%. IR (KBr, cmꢂ1):
1284 (CeN), 1252 (CeN). 1H-NMR (300 MHz, CDCl3):
2.24 (m, 2H,
a green solid and purified by p-TLC using hexane:di-
Acknowledgement
d
CeCH2eC), 3.68 (t, J ¼ 6.2 Hz, 2H, eNeCH2eC), 4.11 (t, J ¼ 6.6 Hz,
2H, eCH2eCI), 6.93 (m, 4H, Ar), 7.19 (m, 4H, Ar) ppm. 13C-NMR
Walter Vivot and Luciana Karayan are acknowledged for their
assistance. This research was supported in part by the CONICET and
SECYT/UBA (Argentina).
(125 MHz, CDCl3): d 29.6, 42.4, 44.0, 115.6, 122.8, 125.7, 127.3, 127.6,
145.0 ppm. HRMS (ESI): calcd for C15H14NSClNa, 298.0427, found,
298.0428.
References
5.1.3.2. 10-(2-Chloroetyl)-10H-phenothiazine 9. This compound
was obtained as a green solid and was purified by p-TLC using as
eluent hexane:dichloromethane (1:1 v/v). Mp: 94e95 ꢁC, yield 85%.
The physical and spectroscopic data were consistent with those
previously reported in the literature [25].
[1] F.C. Odds, Trends Microbiol. 8 (2000) 200e201.
[2] G.S. Martin, D.M. Mannino, S. Eaton, M. Moss, N. Engl. J. Med. 348 (2003)
1546e1554.
[3] M.B. Edmond, S.E. Wallace, D.K. McClish, M.A. Pfaller, R.N. Jones, R.P. Wenzel,
Clin. Infect. Dis. 29 (1999) 239e244.
[4] M. Morrell, V.J. Fraser, M.H. Kollef, Antimicrob. Agents Chemother. 49 (2005)
3640e3645.
[5] K. Mühlemann, C. Wenger, R. Zenhaüsem, M.G. Täuber, Leukemia 19 (2005)
545e550.
5.2. Antifungal activity
Compounds described above (1e12 and 15) were evaluated by
diffusion methodology as screening. From all, halo of inhibition was
observed only for PIP, PMZ, compound 1 and 6. Then, the antifungal
activity of these four compounds and several antifungal agents in
clinical use against yeasts and molds were evaluated following the
CLSI (Clinical and Laboratory Standards Institute) guidelines
(formerly NCCLS), document M27A2 and M38A2 [28,29]. The drugs
evaluated were: amphotericin B (AMB), itraconazole (ITZ), fluco-
nazole (FCZ), terbinafine (TBF), flucytosin (5FC), PIP, PMZ,
compound 1 and compound 6. The assayed yeasts were: Candida
albicans, Candida parapsilosis, Candida glabrata, Candida krusei,
Candida guillermondii, Cryptococcus neoformans. The filamentous
fungi included: Aspergillus fumigates, Aspergillus flavus, Aspergillus
niger, Aspergillus nidulans, Aspergillus terreus, Cladophialophora
carrionii and black yeasts: Exophiala spinifera, Exophiala oligo-
sperma, Exophiala xenobiotica. Briefly fungi were growth onto
Saboureaud glucose agar, during 2 days for yeasts and up to 7 days
for the molds. For each drug, stock solutions were prepared and
diluted in the appropriate solvent to be inoculated into 96-well-
flat-bottom micro titer plates. Fungi inoculum was prepared
according with the CLSI and inoculated into the plates. Final inoc-
ulums for yeasts was 0.5e5 ꢀ103 CFU/ml, and for filamentous fungi
0.5e5 ꢀ104 CFU/ml. After incubation at 30 ꢁC, spectrophotometer
and visual reading were determined in order to obtain the minimal
inhibitory concentration (MIC) for each strain and each drug.
Compound 1 was tested against all strains. Halo of inhibition
was observed by diffusion test, but, when microdilution was per-
formed, all strains showed MICs >512 ug/ml, indicating lacking of
activity. Activity was observed for PIP and PMZ at concentrations
ranged from 128 to 512 ug/ml, with the exception of Aspergillus
[6] R.P. Rapp, Pharmacotherapy 24 (2004) 4Se28S.
[7] M.K. El-Said, Pharmazie 36 (1981) 678e679.
[8] R. Tilak, R. Tyagi, B. Goel, K.K. Saxena, V.K. Srivastava, A. Kumar, Indian Drugs
35 (1998) 216e221 Chem. Abstr. 129 (1998) 109052.
[9] J.N. Dominguez, S. Lopez, J. Charris, L. Iarruso, G. Lobo, A. Semenow, J.E. Olson,
P.J. Rosenthal, J. Med. Chem. 40 (1997) 2726e2733.
[10] G. Lin, K.K. Midha, E.M. Hawes, J. Heterocycl. Chem. 28 (1991) 215e219.
[11] J. Raval, K.K. Desai, ARKIVOC xiii (2005) 21e28.
[12] M. Viveros, L. Amaral, Int. J. Antimicrob. Agents 17 (2001) 225e228 Chem.
Abstr. 134 (2001) 350521.
[13] A. Trivedi, A. Siddiqui, V. Shah, ARKIVOC ii (2008) 210e217.
[14] N. Motohashi, M. Kawase, S. Saito, H. Sakagami, Curr. Drug Targets 1 (2000)
237e245 (Pub Med ID 11465073).
[15] N. Motohashi, T. Kurihara, K. Satoh, H. Sakagami, I. Mucsi, R. Pusztai, Molnar,
Anticancer Res. 19 (1999) 1837e1842.
[16] T. Kurihara, N. Motohashi, G.L. Pang, M. Higno, K. Kiguchi, Molnar, Anticancer
Res. 16 (1996) 2757e2765.
[17] D. Ledincer, L.A. Mitscher, Organic Chemistry of Drug Synthesis, vol. 1 (1976)
372e392.
[18] A.A. Borbely, M. Loepfe-Hinkkanen, Mod. Pharmacol. Toxicol. 16 (1979)
403e426.
[19] W.R. Reid, J.R. Wright, H.G. Kollofe, J.H. Hunter, J. Am. Chem. Soc. 70 (1948)
3100e3102.
[20] I. Meier, Med. Monatsschr. 8 (1954) 397e399 Chem. Abstr. 48 (1954) 10225.
[21] R.G. Vitale, J. Afeltra, J.F.G.M. Meis, P.E. Verweij, Mycoses 50 (2007) 270e276.
[22] G.P. Sarmiento, G.Y. Moltrasio, A.G. Moglioni, ARKIVOC vii (2009) 33e41.
[23] S. Darvesh, R.S. McDonald, A. Penwell, S. Conrad, K.V. Darvesh, D. Mataija,
G. Gomez, A. Caines, R. Walsh, E. Martin, Bioorg. Med. Chem. 13 (2005)
211e213.
[24] J.P. Raval, K.R. Desai, ARKIVOC xiii (2005) 21e28.
[25] L. Della Ciana, I. Hamachi, T. Meyer, J. Org. Chem. 54 (1989) 1731e1735.
[26] H.R. Howard, B.K. Koe, A. Weissman, J. Med. Chem. 32 (1989) 437e444.
[27] S.K. Srivastava, S.K. Nema, A. Srivastava, Ind. J. Chem. 47B (2008) 606e612.
[28] National Committee for Clinical Laboratory Standards (2003). Reference
method for broth dilution susceptibility testing of yeasts: approved standard.
M27A2.
[29] National Committee for Clinical Laboratory Standards (2008). Reference
method for broth dilution susceptibility testing of filamentous fungi:
approved standard. M38A2.